Upstream Bio, Inc.'s Lock-Up Period Set To End on April 9th (NASDAQ:UPB)

Upstream Bio's (NASDAQ:UPB - Get Free Report) lock-up period will end on Wednesday, April 9th. Upstream Bio had issued 15,000,000 shares in its initial public offering on October 11th. The total size of the offering was $255,000,000 based on an initial share price of $17.00. After the end of the company's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

Upstream Bio Trading Down 3.2 %

Shares of UPB stock traded down $0.20 during mid-day trading on Friday, reaching $6.10. The company's stock had a trading volume of 212,237 shares, compared to its average volume of 324,380. The firm's 50 day moving average is $8.27. Upstream Bio has a 12-month low of $5.60 and a 12-month high of $29.46.

Institutional Investors Weigh In On Upstream Bio

A number of large investors have recently modified their holdings of the stock. BNP Paribas Financial Markets acquired a new position in Upstream Bio during the 4th quarter worth approximately $25,000. US Bancorp DE acquired a new position in shares of Upstream Bio during the fourth quarter worth $27,000. Legal & General Group Plc acquired a new position in shares of Upstream Bio during the fourth quarter worth $28,000. Summit Investment Advisors Inc. purchased a new position in shares of Upstream Bio in the fourth quarter valued at $30,000. Finally, Tower Research Capital LLC TRC acquired a new stake in Upstream Bio during the 4th quarter valued at $47,000.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.